Company Information

CSL Behring is a global leader in the biotherapeutics industry with a dynamic portfolio of lifesaving innovations that treat bleeding disorders, immune deficiencies, inherited respiratory disease, hereditary angioedema and neurological conditions. Committed to saving and improving the lives of people with rare and serious medical disorders, we research, develop, manufacture and market plasma-derived and recombinant biotherapies.
Our drive to innovate is reflected in our 1,100 dedicated R&D experts who focus on solving patients’ unmet needs every day. Their work has resulted in a robust pipeline of promising new therapies. We have also created one of the largest and most efficient plasma collection networks in the world in order to ensure a continuous supply of our lifesaving therapies to patients.

Delivering on promises is what we do. A century ago in Melbourne, Australia, CSL Behring’s parent company, CSL Limited, made a promise to save lives and protect the health of people. Today, with operations in more than 30 countries and over 17,000 employees, that promise has never been stronger.

For more information visit 


CSL Limited Business Structure
CSL Behring Fact Sheet CSL Behring
Fact Sheet (PDF)
CSL Behring Product Portfolio CSL Behring
Product Listing (PDF)
CSL Behring Novel Recombinants CSL Behring
Novel Recombinants >
Global Leadership Group Global
Leadership Group >
CSL Limited Annual Report CSL Limited
Annual Report >
CSL Limited Corporate Responsibility Report CSL Limited
Corporate Responsibility Report >
CSL Limited Product Pipeline CSL Limited
Product Pipeline >

LinkedIn Twitter Facebook Google+